Two-Year Results of Photodynamic Therapy With or Without Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy
Two-Year Results of Photodynamic Therapy With or Without Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy
复制标题
DOI：
10.1089/jop.2013.0044
复制
发表时间：
2013-11-01
影响因子：
2.3
通讯作者：
Iijima, Hiroyuki
中科院分区：
文献类型：
--
作者：
Sakurada, Yoichi;Iijima, Hiroyuki
目的：比较光动力疗法(PDT)联合或不联合玻璃体内注射雷尼比单抗(IVR)治疗息肉状脉络膜血管病(PCV)的2年疗效。方法：对58例首次治疗后随访2年以上的PCV患者的病历资料进行回顾性分析。比较34例单纯PDT治疗的患者和24例PDT联合IVR治疗的患者的视力结果，并用多元回归分析影响两年视力结果的相关因素。结果：光动力疗法组术后12个月最佳矫正视力的最小分辨角对数较治疗前明显改善(P=0.026.0 1)，但与术后2 4个月比较差异无统计学意义(P=0.2 1)。而logMAR BCVA在术后12个月明显改善，并在第2个12个月期间一直维持(P
Purpose: To compare the 2-year outcomes of photodynamic therapy (PDT) with or without intravitreal ranibizumab (IVR) for polypoidal choroidal vasculopathy (PCV). Methods: Medical charts from 58 patients with PCV, who had been followed up for more than 2 years after initial treatment, were reviewed retrospectively. Visual outcomes were compared between 2 groups, consisting of 34 patients treated with PDT monotherapy without IVR and 24 with the combination of PDT and IVR, and the factors associated with the 2-year visual outcomes were investigated using multiple regression analysis. Results: In the PDT monotherapy group, the logarithm of the minimum angle of resolution (logMAR) of the best-corrected visual acuity (BCVA) improved significantly at 12 months (P=0.026), but was not significantly different from the initial logMAR BCVA at 24 months (P=0.21). By contrast, the logMAR BCVA improved significantly at 12 months and was maintained throughout the second 12-month period (P